FDA Approves Durvalumab for Treatment of Adults Patients With LS-SCLC
Published: December 5th 2024 | Updated: December 5th 2024The indication is for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy.
Read More
Shaping the Future of Pharmacy: Trends to Watch at ASHP Midyear 2024
December 4th 2024Key trends shaping the future of health-system pharmacy include advanced medication management to address supply chain challenges, digital transformation to enhance pharmacy operations, and strategies for compliance with evolving regulations, all of which will be central topics at the ASHP Midyear 2024 meeting.
Read More
The Power of Our Voice: Why Pharmacists Must Advocate for Our Profession
December 4th 2024Advocacy ensures that policymakers understand the realities on the ground. If we fail to speak up, decisions about our profession will be made without our input—often by individuals who lack the expertise and perspective we bring to the table.
Read More
Social Determinants of Health Shape Outcomes in C difficile Infections
December 4th 2024Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses a study she conducted that highlights how social determinants of health exacerbate severity and increase rates of mortality from Clostridioides difficile infections in vulnerable communities.
Read More
FDA Receives 2 Supplemental Biologics License Applications for Guselkumab for Pediatric Indications
December 3rd 2024If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.
Read More
Precision Oncology: Expanding Therapeutic Horizons With Trastuzumab Deruxtecan
December 3rd 2024The tumor-agnostic FDA approval of T-DXd for HER2-positive unresectable or metastatic solid malignancies exemplifies the importance of understanding the risks associated with targeted therapy and the need for proactive monitoring strategies.
Read More